Zobrazeno 51 - 60
of 108
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
James S. Trimble, Keiran S.M. Smalley, Ragini R. Kudchadkar, Vernon K. Sondak, L. Frank Glass
Publikováno v:
Clinics in Dermatology. 31:200-208
Since the discovery of activating mutations in the BRAF oncogene in melanoma, there has been remarkable progress in the development of targeted therapies for unresectable and metastatic melanoma. We review the latest developments in our understanding
Autor:
Jonathan S. Zager, Geoffrey T. Gibney, James J. Mulé, Jeffrey S. Weber, Suroosh S. Marzban, Shari Pilon-Thomas, Vernon K. Sondak, Amod A. Sarnaik, Erica Royster, Ragini R. Kudchadkar, Lisa Kuhn, William J. Janssen, Sabine Ellwanger
Publikováno v:
Journal of Immunotherapy. 35:615-620
A single-institution pilot clinical trial was performed combining nonmyeloablative chemotherapy and the adoptive transfer of tumor-infiltrating lymphocytes with interleukin-2 in patients with metastatic melanoma. Nineteen patients were enrolled with
Autor:
Mohammad K. Khan, David H. Lawson, Ragini R. Kudchadkar, Jeffrey M. Switchenko, Mudit Chowdhary, Roshan S. Prabhu, Kirtesh R. Patel, Richard J. Cassidy
Publikováno v:
Melanoma research. 26(4)
We retrospectively compared the outcomes and toxicities of melanoma brain metastases (MBM) patients treated with BRAF inhibitors (BRAFi) and stereotactic radiosurgery (SRS) with SRS alone. We identified 87 patients with 157 MBM treated with SRS alone
Autor:
Ricardo J. Gonzalez, Geoffrey T. Gibney, Leslie M. Turner, Ragini R. Kudchadkar, Keiran S.M. Smalley, Timothy W. McCardle, Jacob J. Benedict, Sarah Sloot, Vernon K. Sondak, Jonathan S. Zager, Jeffrey S. Weber, Jane L. Messina, R. C. DeConti
Publikováno v:
Melanoma Research, 26(1), 83-87. LIPPINCOTT WILLIAMS & WILKINS
Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16d38f31c0846b2de9e11dd6e633516
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
https://research.rug.nl/en/publications/e7053d76-4bbe-428d-9d29-4187e5918d44
Publikováno v:
Seminars in Oncology. 39:139-144
Basal cell carcinoma (BCC) is the most common tumor of the skin and can result in significant morbidity as well as costs. The discovery of aberrant Hedgehog (HH) signaling in patients with genetic propensity to develop BCCs has resulted in a better u
Autor:
Douglas C. Parker, Ragini R. Kudchadkar, Kirtesh R. Patel, Daniel E. Oliver, Jeffrey M. Switchenko, Keith A. Delman, Mohammad K. Khan, David H. Lawson
Publikováno v:
Melanoma research. 26(1)
Current guidelines are unclear as to the precise role of radiotherapy (RT) in patients with desmoplastic melanoma (DM). The purpose of this study was to evaluate our institutional outcomes in patients with DM, and to explore the roles of both adjuvan
Autor:
Anja K. Bosserhoff, Andrew E. Aplin, Marcus Bosenberg, Ragini R. Kudchadkar, Christoph Hoeller, Antoni Ribas, Raymond L. Barnhill, Nikolas K. Haass, Keiran S.M. Smalley, Keith T. Flaherty, Jane L. Messina
Publikováno v:
Pigment Cell & Melanoma Research. 25:E1-E11
Autor:
Mehmet Asim Bilen, Bradley C. Carthon, Bassel F. El-Rayes, Haydn T. Kissick, Olatunji B. Alese, David H. Lawson, Rathi N. Pillai, Dylan J. Martini, Conor E. Steuer, Mehmet Akce, Viraj A. Master, Walid L. Shaib, Hannah Collins, R. Donald Harvey, Colleen Lewis, Christina Wu, Ragini R. Kudchadkar, Taofeek K. Owonikoko, Suresh S. Ramalingam, Yuan Liu
Publikováno v:
Cancer Research. 78:2607-2607
Background: Optimal biomarkers for cancer pts treated with IO are currently lacking. Markers of inflammation, such as neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) are readily availab
Autor:
David H. Lawson, Rafi Ahmed, Mohammad K. Khan, Lily Masoumy, Suresh S. Ramalingam, Alice O. Kamphorst, Tahseen H. Nasti, Ragini R. Kudchadkar, Taofeek K. Owonikoko, Melinda I Yushak
Publikováno v:
Journal of Clinical Oncology. 36:e21542-e21542
e21542Background: Brain metastases occur in 15–40% of patients (pts) with systemic cancers, such as lung and melanoma. The standard of care for brain metastases is radiation therapy. Methods to min...